AstraZeneca announced a $2 billion U.S. investment to expand biologics manufacturing in Maryland, nearly doubling capacity at Frederick and building a new clinical facility in Gaithersburg to support biologics and rare‑disease portfolios. The project emphasizes AI, automation and environmental standards and is projected to support thousands of jobs and domestic supply resilience when operational in 2029. Separately, Thermo Fisher priced a €2.1 billion senior notes offering to support general corporate purposes including possible acquisitions and refinancing, signaling continued finance activity in life‑science infrastructure. The company indicated proceeds could fund strategic growth as demand for analytical and biomanufacturing tools remains elevated. These capital commitments underscore the industry’s pivot to onshore biologics capacity and platform investments, highlighting a wave of infrastructure build‑out that will affect CDMO capacity, supply chains and regional hiring over the next several years.